Načítá se...
A comparison of adverse event and fracture efficacy data for strontium ranelate in regulatory documents and the publication record
OBJECTIVE: Recently, the European Medicines Agency reported that strontium ranelate increases myocardial infarction risk in postmenopausal women, 8.5 years after it was registered for use in osteoporosis. Unreported serious adverse events in clinical trials for other pharmaceuticals have been descri...
Uloženo v:
| Hlavní autoři: | , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BMJ Publishing Group
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4187454/ https://ncbi.nlm.nih.gov/pubmed/25293384 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2014-005787 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|